Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts
BioSpace
After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M A action from other big names, including Novartis, Amgen and AbbVie.
pharminent
April 3, 2026 (Last updated: April 3, 2026)
BioSpace
After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M A action from other big names, including Novartis, Amgen and AbbVie.